Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)

NCT04768062 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT04768062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04768062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)
Lead sponsor
NS Pharma, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
April 13, 2021
Completion date
November 30, 2025
Enrollment
74 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy